Drug Excipient Compatibility, Development and Preliminary Clinical Studies of Tizanidine Hydrochloride Floating Drug Delivery System




  • Kishan V
  • Swathi Yambadi
  • Ramesh Bomma


The objective of this investigation was to develop formulation of floating matrix tablets of tizanidine HCl to prolong the gastric residence time by using hydroxy propyl methyl cellulose (HPMC K15M) or xanthan gum as sole release retardant and to check the clinical response. The drug-excipients compatibility studies were conducted using DSC and also by visual observation. Incorporation of NaHCO3 in the formulation resulted incompatibility with drug and therefore, the composition was modified by replacing NaHCO3 with CaCO3 in remaining formulations. Floating matrix tablets of tizanidine were developed by direct compression method and the developed ten formulations exhibited satisfactory physicochemical characteristics and in-vitro buoyancy. Formulation (F9) was selected as optimized formulation based on physicochemical characters, in-vitro buoyancy and drug release, and was used in in-vivo radiographic studies in human volunteers by incorporating BaSO4. In radiographic studies, the gastric retention time of floating tablets was found to be 4 ± 0.86 h (n=3). Optimized floating tablets (F9) were used to know the clinical effects in patients suffering from spasticity under the observation of clinician. The optimized tizanidine HCl floating matrix tablets were developed and found to have gastric retention behaviour in stomach and further were found to have good clinical effects in patients suffering from spasticity during preliminary clinical studies.


Download data is not yet available.


Metrics Loading ...


Drug-excipient compatibility, buoyancy, gastric retention time, tizanidine




How to Cite

V K, Yambadi S, Bomma R. Drug Excipient Compatibility, Development and Preliminary Clinical Studies of Tizanidine Hydrochloride Floating Drug Delivery System. Scopus Indexed [Internet]. 2021 Jan. 1 [cited 2024 Jun. 20];14(1):5334-42. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/1278



Research Articles


Amarnath Reddy R, Ramesh B and Kishan V (2013). Drug-excipient interaction during formulation development, in vitro and in vivo evaluation of gastroretentive drug delivery system for nizatidine. Int J Pharm Sci Nano Tech 6(4): 2281-2293.

Brahma NS and Kim KH (2000). Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention, J Control Release 63: 235-259.

Caldwell LJ, Gardner RC and Cargill RC (1998). Drug delivery device which can be retained in the stomach for a controlled period of time. US patent 4 735 804.

Deshpande AA, Rhodes CT, Shah NH and Malick AW (1996). Controlled-release drug delivery systems for prolnged gastric residence time: An overview. Drug Dev Ind Pharm 22(6): 531- 539.

El Gamal SS, Naggar VF and Allam AN (2011). Optimization of acyclovir oral tablets based on gastroretention technology: Factorial design analysis and physicochemical characterization studies. Drug Dev Ind Pharm 37(7): 855–867.

Fix JA, Cargill R and Engle K (1993). Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers. Pharm Res. 10(7): 1087-1089.

Gröning R and Heun G (1989). Dosage forms with controlled gastrointestinal passage - studies on the absorption of nitrofurantoin. Int J Pharm 56: 111-116.

Harshita B, Sandeep V, Madhusudan Reddy A and Srinivasa Babu P (2014). Formulation and evaluation of gastroretentive delivery of

tizanidine hydrochloride using natural polymers, Int J Pharm Sci Res 5(4): 1533-1538.

Higuchi T (1963). Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52(12): 1145-1149.

Hwang SJ, Park H and Park K (1998). Gastric retentive drug delivery systems. Crit Rev Ther Drug Carrier Syst 15(3): 243-84. Kokate A, Marasanapalle VP, Jasti BR and Xiaoling Li (2006). Physiological and biochemical barriers to the drug delivery. In: Design of Controlled Release Drug Delivery Systems (Jasti BR, Ed.), Mc Graw-Hill, New York, pp. 41-74.

Korsmeyer RW, Gurny R, Doelker E, Buri P and Peppas NA (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15(1): 25-35.

Lazarus J and Cooper J (1961). Absorption, testing, and clinical evaluation of oral prolonged action drugs. J Pharm Sci 50(9): 715–32.

Lehr CM (1994). Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 11(2-3): 119-160.

Malinowski HJ and Marroum PJ (1999). Food and drug administration requirements for controlled release products. In: Encyclopedia of controlled drug delivery, Vol. 1 (Mathiowitz E, Ed.), John Wiley and Sons Inc., New York, pp. 381-395.

Mamajek RC and Moyer ES (1980). Drug-dispensing device and method. US Patent 4 207 890.

Martindale (2007). Muscle relaxants. The Complete Drug Reference. Sweetman C, 35th edition: 1738.

Ramesh B and Kishan V (2013). Development of gastroretentive drug delivery system for cefuroxime axetil: In vitro and In vivo evaluation in human volunteers. Pharm Dev Tech 18(5): 1230- 1237.

Ramesh B and Kishan V (2013). Development, Intragastric performance and pharmacokinetic study of gastroretentive drug delivery system for cefdinir in human volunteers. Int J Drug Delivery 5(1): 63-72.

Ramesh B, Appala Swamy Naidu R, Madhusudan Rao Y and Kishan V (2009). Development and evaluation of gastroretentive norfloxacin floating tablets. Acta Pharm 59: 211-221.

Rosa MJC, Ziaa H, and Rhodes CT (1994). Designing and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 105(1): 65-70.

Rouge N, Buio P, and Doelker E (1996). Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 136(1-2): 117-139.

Senthil A, Rahul GR, Prashanth SS, Sonal UK, and Narayana Swamy VB (2011). Formulation and evaluation of floating tablets of tizanidine HCl. Int Res J Pham 2(8): 117-139

Someshwar K, Kalyani Ch, Ramarao T, and Kalyan Kumar KK (2011). Formulation and evaluation of effervescent floating tablets of tizanidine hydro-chloride, Acta Pharm. 61: 217-226.

Sushma A, Ramesh B and Kishan V (2016). Design, in vitro and in vivo Evaluation of Gemifloxacin Mesylate Floating Matrix Tablets. Int J Pharm Sci Nano Tech 9(1): 3143-50.

Wagner JG (1969). Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 58(10): 1253-1257.

Wagner JG (1971). Biopharmaceutics and pharmaco-kinetics. 1st ed. Org. Intelligence publications, 22: 148-157.

Whitehead L, Fell JT, Collett JH, Sharma HL, and Smith AM (1998). Floating dosage forms: an in vivo study demonstrating prolonged gastric retention, J. Control. Rel. 55: 3-12.

Most read articles by the same author(s)